Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

What Was Tested

Researchers studied Teriparatide in this randomized controlled trial publication.

This study investigated the effects of a single administration of teriparatide on bone turnover markers in postmenopausal women.

Who Took Part

The abstract describes 30 women taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

Neither the women nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

What Was Measured

The subject headings attached to it are Biomarkers, Bone Density Conservation Agents, Bone Remodeling, Bone Resorption, Calcium, Osteogenesis and Postmenopause.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide in 30 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.